Lundbeck names Tarek Samad as EVP, head of R&D from Sept. 1

• Lundbeck named Tarek Samad EVP, head of R&D, joining the executive leadership team effective Sept. 1, 2026.
• Samad succeeds Johan Luthman, who will retire; a transition starts in July, with Luthman staying through end-2026.
• Samad is SVP, global head of research and corporate patents; he has led global research since 2021.
• Before Lundbeck, Samad held senior research roles at Immunitas Therapeutics, Sanofi, Pfizer; he also served at Harvard Medical School and Massachusetts General Hospital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief via Cision (Ref. ID: 20260624:BIT:1075:0) on June 24, 2026, and is solely responsible for the information contained therein.